60 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
financing environment. In this context, Sutro is continuing its process of evaluating its programs and spending.
Unrealized Gain from Increase in Value
8-K
EX-99.2
STRO
Sutro Biopharma Inc
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
position, industry environment and potential market opportunities. Forward-looking statements are subject to known and unknown risks, uncertainties
8-K
EX-99.1
STRO
Sutro Biopharma Inc
13 Nov 23
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
conditions provide a challenging financing environment. In this context, Sutro is evaluating its programs and spending as it fully develops its 2024 goals
8-K
EX-99.2
STRO
Sutro Biopharma Inc
9 Sep 20
Other Events
5:23pm
, competitive position, industry environment and potential market opportunities. Forward-looking statements are subject to known and unknown risks
8-K
EX-99.2
STRO
Sutro Biopharma Inc
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
, competitive position, industry environment and potential market opportunities. Forward-looking statements are subject to known and unknown risks
8-K
EX-99.2
ieqdbpjrfccz
19 May 21
Regulation FD Disclosure
5:00pm
8-K
EX-99.2
tmb 48ui2w
10 Nov 21
Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones
7:03am
8-K
EX-99.2
7j90ileccocylew9k
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
upz gg3rjpy7fq5hjegr
9 Sep 20
Other Events
5:23pm
8-K
EX-99.1
voh hrg4i
10 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
02efktmv5 1qt06q
16 Jun 22
Other Events
7:00am
8-K
EX-99.1
9laaz53 va4w76q8x62n
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm
8-K
EX-99.1
hgpbp723nju q7j58
15 Jun 20
Regulation FD Disclosure
7:21am
PRE 14A
zo9 xg8wlu7yu
14 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.1
k1gtcnr 1lu6
8 Jan 24
Results of Operations and Financial Condition
7:31am
DRS
EX-10.9
ovyl 0ou7d8xfpv6n
1 Jun 18
Draft registration statement
12:00am
S-3
EX-1.2
g64y4056vgcwjbeezdm
4 Oct 19
Shelf registration
4:06pm
DEF 14A
dhvefa40
26 Apr 19
Definitive proxy
12:00am